Magnesium Sulfate: Nursing Drug Guide, Hypermagnesemia & NCLEX Review

Magnesium sulfate is supplied primarily as a generic injectable—commonly as a 50% (500 mg/mL) solution that must be diluted before IV infusion per labeling. Premixed bags (e.g., magnesium sulfate in 5% dextrose) are also used in many hospitals. Always read the vial or bag concentration; mg, grams, and mEq conversions are a frequent source of medication errors.

Oral magnesium salts (e.g., magnesium oxide, citrate) are different products with distinct absorption and toxicity profiles—do not substitute oral laxative or supplement products for parenteral orders.

Hospira magnesium sulfate injection labeling lists parenteral use as an electrolyte replenisher or anticonvulsant. Nurses most often administer it for documented hypomagnesemia, seizure prevention/control in hypertensive disorders of pregnancy, and select cardiac or neurologic indications per prescriber and institutional protocol.

↔On a small screen, swipe or scroll sideways to see the full table.

Magnesium is an essential cofactor for enzymatic reactions and modulates neuromuscular transmission. Parenteral magnesium prevents or controls convulsions by blocking neuromuscular transmission and decreasing acetylcholine release at the motor end plate. It also acts peripherally as a vasodilator—low doses may cause only flushing and sweating; larger doses lower blood pressure. Normal plasma magnesium is about 1.5 to 2.5 mEq/L. Toxicity progresses with rising levels: reflexes diminish above ~4 mEq/L; respiratory paralysis may occur near ~10 mEq/L; heart block may occur at lower levels in some patients per labeling.

Dose must be carefully adjusted to individual requirements and response; discontinue as soon as the desired effect is obtained. Institutional protocols and product formulations may vary—always verify orders with pharmacy for concentration, rate, and maximum 24-hour dose.

Renal impairment: Use with caution; maximum dosage in severe renal insufficiency is 20 g in 48 hours with frequent serum magnesium levels per labeling. Parenteral use in renal insufficiency may lead to magnesium intoxication.

Hepatic impairment: Not specified in the reviewed prescribing information for dose adjustment.

Missed dose: Not specified in the reviewed prescribing information; for continuous infusions, follow protocol and notify prescriber if interruption occurs.

• IV anticonvulsant onset: Immediate; duration about 30 minutes per labeling
• IM: Onset in about 1 hour; persists 3 to 4 hours
• Effective anticonvulsant serum levels: About 2.5 to 7.5 mEq/L (labeling also cites 3 to 6 mg/100 mL [2.5 to 5 mEq/L] for convulsion control in toxemia)
• Excretion: Renal only, proportional to plasma concentration and glomerular filtration

Pretreatment checks

• Confirm indication and that hypomagnesemia is documented when replacement is ordered
• Test patellar reflex (knee jerk) and respiratory rate—labeling cites ~16 breaths/min or more as a safe regimen indicator
• Urine output ≥100 mL in the 4 hours before each dose (when applicable per labeling)
• Serum magnesium level when available; creatinine/eGFR for renal clearance risk
• Review CNS depressants: opioids, barbiturates, sedatives, systemic anesthetics—dose adjustment may be needed
• Confirm injectable calcium is immediately available on the unit

Contraindications

• Heart block
• Myocardial damage

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Routes: IV and IM per labeling. 50% solution must be diluted to 20% or less before IV infusion; dilute to 20% or less for IM in infants and children. Inspect for particulates; discard unused portion of single-dose containers.

• IV bolus/infusion: Administer slowly and cautiously to avoid hypermagnesemia; general IV injection rate should not exceed 150 mg/minute (1.5 mL of 10% or equivalent) except in severe eclampsia with seizures per labeling
• Diluents: Commonly 5% dextrose or 0.9% sodium chloride for infusion after dilution
• IM (adults): Deep IM injection of undiluted 50% solution may be used; children require dilution to ≤20%
• Before each repeat parenteral dose: test patellar reflex; if absent, hold magnesium until reflex returns
• Use medication reconciliation and independent double-check for grams, mL, and mEq on high-risk electrolyte orders

• Serum magnesium rising toward therapeutic range for indication (e.g., seizure control in toxemia)
• Absence of new seizure activity when used for eclampsia/pre-eclampsia
• Resolution of hypomagnesemia signs (muscle irritability, tremors, tetany) when replacing deficiency
• Patellar reflex present and respiratory rate adequate between doses
• Improved rhythm stability when used for select tachyarrhythmias per prescriber plan

Hypermagnesemia can progress from subtle reflex changes to life-threatening respiratory depression—especially with renal impairment, rapid administration, or stacked sedatives.

• Absent patellar reflex or diminished deep tendon reflexes
• Respiratory rate below about 16/min, shallow respirations, or rising sedation
• Bradypnea, flaccid paralysis, or inability to protect airway
• Sharp drop in blood pressure, flushing, sweating, or circulatory collapse per intoxication labeling
• Heart block or new conduction changes on monitor—especially if calcium may be needed in a digitalized patient
• Oliguria with rising magnesium level in renal impairment
• Hypocalcemia with tetany reported secondary to magnesium therapy for eclampsia per labeling

↔On a small screen, swipe or scroll sideways to see the full table.

Adverse effects of parenteral magnesium are usually the result of magnesium intoxication—prevention through reflex, respiratory, and renal monitoring is the primary nursing intervention.

Magnesium intoxication manifests as sharp hypotension and respiratory paralysis. Disappearance of the patellar reflex is a useful clinical sign of onset per labeling.

Antidote

Intravenous calcium — labeling directs 10 to 20 mL of a 5% calcium solution (diluted with isotonic sodium chloride if desirable) to antagonize hypermagnesemia. Subcutaneous physostigmine 0.5 to 1 mg may be helpful per labeling.

Management per labeling

• Stop magnesium immediately; provide artificial ventilation until calcium can be given if respiratory paralysis occurs
• Administer IV calcium per prescriber/poison-control protocol; use extreme caution in digitalized patients because serious conduction changes may occur
• Hypermagnesemia in the newborn may require resuscitation, assisted ventilation, and IV calcium per labeling
• Consider dialysis in severe renal impairment with symptomatic hypermagnesemia when indicated by specialist guidance
• Contact poison control or medical toxicology services per facility protocol and local emergency guidance

• Magnesium sulfate vs magnesium hydroxide / oral magnesium — different products and routes; never substitute oral laxative magnesium for IV/IM orders
• 50% concentration (500 mg/mL) — confusing grams, milliliters, and mEq causes tenfold errors; independent double-check with pharmacy
• Premixed bag vs vial push — verify total grams in bag and pump rate; do not infuse undiluted 50% solution IV
• MgSO₄ vs potassium chloride concentrate — both are high-risk electrolytes stored in critical areas; read label three times
• Continuous infusion duplicate orders — reconcile loading dose plus maintenance infusion during handoff to prevent stacking

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Patellar reflex and respiratory rate before each parenteral dose per labeling
• Serum magnesium concentration when ordered—therapeutic anticonvulsant range about 2.5 to 7.5 mEq/L; toxicity signs emerge at higher levels
• Urine output (≥100 mL in 4 hours preceding dose when following labeling guidance)
• Blood pressure, level of consciousness, and muscle strength
• Cardiac rhythm when on concomitant digoxin or in eclampsia protocols
• Fetal monitoring and postpartum newborn status when used in pregnancy per obstetric protocol

Document

• Dose (grams and mEq), concentration, route, rate, and total 24-hour magnesium administered
• Reflex status, respiratory rate, and urine output with each assessment
• Serum magnesium results and time of last level
• Any hold events, calcium administration, or escalation to critical care
• Patient/family teaching on toxicity symptoms and when to call for help

• Report flushing, warmth, weakness, trouble breathing, slurred speech, or chest discomfort immediately
• During labor or postpartum magnesium, call the nurse if you feel unusually sleepy or cannot take a deep breath
• Do not take extra magnesium supplements, laxatives, or antacids unless your prescriber approves
• Understand that IV magnesium requires frequent nurse checks of reflexes and breathing—not optional monitoring
• If breastfeeding after prolonged magnesium therapy, discuss timing of lactation support with your care team
• Know that toxicity is treated with IV calcium in the hospital—seek emergency care per local protocol if symptoms occur after discharge instructions

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for magnesium sulfate using a tabbed antepartum case (MAR, labs, vitals, nursing notes), then priority action, cue recognition SATA, trend SATA after calcium therapy, matrix urgency sorting, administration judgment, and antidote cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.